Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ziltivekimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Novo Nordisk
Deal Size : $2,100.0 million
Deal Type : Acquisition
Novo Nordisk to Acquire Corvidia Therapeutics to Expand Cardiovascular Presence
Details : The acquisition of Corvidia Therapeutics and its lead candidate, ziltivekimab, is aligned with Novo Nordisk’s strategy to expand its presence across a range of cardiometabolic diseases that are closely linked to Novo Nordisk’s core business within di...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $725.0 million
November 06, 2020
Lead Product(s) : Ziltivekimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Novo Nordisk
Deal Size : $2,100.0 million
Deal Type : Acquisition
Lead Product(s) : D6PV
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Early preclinical studies show peptide D6PV has the ability to activate the enzyme called Lipo-Protein Lipase (LPL), rapidly (within 1 -3 hours) reducing the number of triglycerides in the bloodstream
Product Name : D6PV
Product Type : Peptide
Upfront Cash : Inapplicable
January 30, 2020
Lead Product(s) : D6PV
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
